GlassScriptPhysician profile
Mark R Fortson
NPI 1457452591
$2,397.84
in general payments reported to CMS, 2019-2025
27 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $208 · 2021: $286 · 2022: $125 · 2023: $581 · 2024: $501 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.58 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $182.79 | 2023-2024 | Dupixent |
| Genzyme Corporation | $171.74 | 2023-2024 | |
| Janssen Biotech, INC. | $133.26 | 2019-2024 | Stelara |
| Pfizer INC. | $131.53 | 2019-2025 | |
| Grifols USA, LLC | $125.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.07 | 2019-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $118.69 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $105.81 | 2019 | |
| Evoke Pharma, INC. | $99.72 | 2020-2024 | Gimoti |
| Intercept Pharmaceuticals, INC. | $86.92 | 2019-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $67.55 | 2023 | Entyvio, Gattex |
| Enterra Medical, INC. | $62.72 | 2025 | |
| Gilead Sciences, INC. | $59.62 | 2023 | |
| Glaxosmithkline, LLC. | $58.13 | 2025 | Nucala |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.11 | 2021-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $34.45 | 2023 | |
| Shire North American Group INC | $33.03 | 2019 | |
| Harmony Biosciences LLC | $27.29 | 2024 | |
| Medtronic, INC. | $23.54 | 2024 | Interstim |
| Organon LLC | $22.51 | 2023 | Renflexis, Hadlima |
| Covidien LP | $16.46 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.21 | 2023 | Andexxa |
| Fresenius Kabi USA, LLC | $14.62 | 2023 | Idacio |
| Braintree Laboratories, INC. | $13.33 | 2020 | |
| Alfasigma USA, INC. | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fortson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.